NASHVILLE, Tenn., Oct. 12, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited (ASX: MVF), a leading provider of assisted reproductive services, as well as specialist women's imaging and diagnostic services in Australia and Southeast Asia.
Founded in 1971, Monash IVF is a leader in the field of fertility services and one of the largest providers of assisted reproductive technologies (ART) and tertiary-level prenatal diagnostics in Australia and Southeast Asia. With more than 100 locations across Australia, Monash IVF has achieved many Australian and world firsts in the industry. Its operating businesses include Monash IVF, Repromed, Fertility Solutions and KL Fertility Centre. Through this multi-year agreement, Monash IVF and its operating businesses will utilize Cryoport's cryogenic logistics solutions and ISO-certified risk mitigation process for the delivery of patients' reproductive materials throughout Australia and internationally. Reproductive materials may be moved from one clinic to another ...